KODIAK SCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.28 USD | +2.98% |
|
-2.38% | +7.89% |
| Apr. 04 | UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating | MT |
| Apr. 01 | Barclays Raises Price Target on Kodiak Sciences to $3 From $2, Maintains Underweight Rating | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,157 | 7,400 | 4,350 | 372.5 | 158.9 | 171.8 | - | - |
| Enterprise Value (EV) 1 | 2,821 | 6,431 | 3,618 | -106.4 | -126.6 | 113.3 | 163.6 | 114.8 |
| P/E ratio | -57.6 x | -50.5 x | -16.4 x | -1.12 x | -0.61 x | -0.8 x | -0.86 x | -1.76 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | -58 x | -47.4 x | -13.6 x | 0.32 x | 0.49 x | -0.54 x | -0.73 x | -0.44 x |
| EV / FCF | -71.3 x | -71.1 x | -14.7 x | 0.44 x | 0.65 x | -0.57 x | -1.78 x | - |
| FCF Yield | -1.4% | -1.41% | -6.79% | 229% | 155% | -175% | -56.2% | - |
| Price to Book | 9.25 x | 8.72 x | 6.62 x | 0.86 x | 0.6 x | 1.21 x | 10.6 x | 4.89 x |
| Nbr of stocks (in thousands) | 43,884 | 50,370 | 51,305 | 52,025 | 52,286 | 52,370 | - | - |
| Reference price 2 | 71.95 | 146.9 | 84.78 | 7.160 | 3.040 | 3.280 | 3.280 | 3.280 |
| Announcement Date | 3/16/20 | 3/1/21 | 3/1/22 | 3/28/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA 1 | -48.65 | -135.5 | -266 | -337.6 | -259 | -211 | -225.6 | -263.8 |
| EBIT 1 | -49.19 | -136 | -267.1 | -341.4 | -277.3 | -226.6 | -245.9 | -268.3 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -47.36 | -133.1 | -267 | -333.8 | -260.5 | -225.6 | -267.4 | -354.6 |
| Net income 1 | -47.36 | -133.1 | -267 | -333.8 | -260.5 | -225.5 | -267.4 | -354.6 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -1.250 | -2.910 | -5.160 | -6.390 | -4.970 | -4.084 | -3.797 | -1.866 |
| Free Cash Flow 1 | -39.58 | -90.43 | -245.6 | -243.5 | -195.5 | -198 | -92 | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/1/21 | 3/1/22 | 3/28/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -67.28 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -67.54 | -93.05 | -95.77 | -92.07 | -79.48 | -74.07 | -74.62 | -84.83 | -54.5 | -63.37 | -57.56 | -56.33 | -56.19 | -56.61 | -48.67 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -67.53 | -93.16 | -95.71 | -90.63 | -77.04 | -70.45 | -70.78 | -80.19 | -50.01 | -59.52 | -56.25 | -53.75 | -52.35 | -51.4 | - |
| Net income 1 | -67.53 | -93.16 | -95.71 | -90.63 | -77.04 | -70.45 | -70.78 | -80.19 | -50.01 | -59.52 | -56.25 | -53.75 | -52.35 | -51.4 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.300 | -1.790 | -1.830 | -1.740 | -1.470 | -1.350 | -1.350 | -1.530 | -0.9500 | -1.130 | -1.034 | -1.014 | -1.016 | -1.023 | -0.8885 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/1/22 | 5/10/22 | 8/9/22 | 11/9/22 | 3/28/23 | 5/15/23 | 8/14/23 | 11/14/23 | 3/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 336 | 969 | 732 | 479 | 286 | 58.4 | 8.2 | 56.9 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -39.6 | -90.4 | -246 | -243 | -196 | -198 | -92 | - |
| ROE (net income / shareholders' equity) | -21.9% | -22.1% | -35% | -60.7% | -74.2% | -96.6% | -236% | -493% |
| ROA (Net income/ Total Assets) | -21% | -18.7% | -27.1% | -42.5% | -45.5% | -49% | - | - |
| Assets 1 | 225.5 | 713.1 | 985.8 | 785.4 | 573 | 460.6 | - | - |
| Book Value Per Share 2 | 7.780 | 16.80 | 12.80 | 8.330 | 5.060 | 2.710 | 0.3100 | 0.6700 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.44 | 7 | 17 | 37 | 41.4 | 11.2 | 2.58 | 2.56 |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/1/21 | 3/1/22 | 3/28/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
3.28
USD
Average target price
4.25
USD
Spread / Average Target
+29.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.89% | 172M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- KOD Stock
- Financials Kodiak Sciences Inc.
